Although the study results do not lead to definite clinical conclusions, they encourage further clinical investigations on GLP-1R as a potentially actionable target in MCI/AD and on sex-related differences in the treatment responses to GLP-1 RA. This evidence concerns the gene GLP1R and Alzheimer disease.